Plasmin is a complex enzyme that performs major roles in removal of blood clots, wound healing and in tumor metastasis. Here we will understand how plasmin function is regulated at the molecular level. These key insights will be of future use in the development of therapeutics targeting the plasmin system in cancer and clotting diseases.
A specialised set of T lymphocytes called Mucosal Associated Invariant T (MAIT) cells react against bacteria and yeast, and reside at mucosal sites where the body's immune defences are most easily breached, e.g. respiratory tract and intestinal mucosa. This study investigates the role of MAIT cells in both protection and pathology in bacterial infections. Controlling MAIT cells could help in treating these conditions.
Targeting Adenosine Mediated Immunosuppression To Enhance CAR T Cell Activity
Funder
National Health and Medical Research Council
Funding Amount
$633,447.00
Summary
The use of white blood cells genetically engineered to eradicate cancer cells specifically has been a major breakthrough in cancer treatment. These cells (CAR T cells) are very effective in blood cancers, but do not currently work well in other cancers. This is due to the immune suppressing nature of the cancer environment. I propose to use strategies to overcome this by genetically reprogramming the CAR T cells to be resistant to suppression by the cancer and therefore be more effective.
The Mezzanine T Cell Response: Intervening At The Coal Face
Funder
National Health and Medical Research Council
Funding Amount
$765,585.00
Summary
In an initial immune response, specialised cells in lymph nodes tell T cells to multiply; the stimulated T cells depart and enter target tissue (e.g. lung in the case of flu). We describe a new response whereby the target tissue itself can tell T cells to multiply further. This response in target tissues reveals a new way of altering immune responses. This is especially important as in many diseases, the primary lymph node response has already occurred, so cannot be therapeutically intervened.
A Novel Molecular Mechanism Controlling Myelopoiesis
Funder
National Health and Medical Research Council
Funding Amount
$878,439.00
Summary
The immune system is comprised of many different cell types, each with a specialised function. Many are short-lived and must be continually replenished throughout life. Abnormalities in this process underlie many human diseases, including immunodeficiency, autoimmunity and cancer. We have discovered a novel molecular mechanism that is critical for the production of immune cells. This project will investigate how this mechanism is controlled and the impacts on myelodysplastic syndromes.
Biofocussed Prostate Cancer RadioTherapy (BiRT): A Personalised Approach To Delivering The Right Dose To The Right Place
Funder
National Health and Medical Research Council
Funding Amount
$753,565.00
Summary
We propose a new approach to treating prostate cancer with radiotherapy to move from the standard whole prostate treatment to a personalised treatment that varies radiation intensity throughout the prostate. We will mathematically combine features that influence radiotherapy effect from advanced imaging, clinical and biopsy information. This model will map out the radiotherapy dose required at each part of the prostate, to maximise killing of the cancer whilst minimising harm to normal tissue
A Stem Cell-specific MicroRNA-independent Function Of Drosha
Funder
National Health and Medical Research Council
Funding Amount
$637,702.00
Summary
Stem cells are responsible for producing and replenishing the ~200 specialised cell types in our body. Our goal is to understand the molecular switches that control the function of these cells. We recently discovered that the activity of certain genes within stem cells is controlled by degradation. This degradation is absolutely crucial for safeguarding the function of stem cells. This project will investigate how this novel mechanism is controlled within these cells.
Next Generation Brain-Machine Interface: Minimally-Invasive Endovascular Stent-Electrode Array For Robotic Limb Control
Funder
National Health and Medical Research Council
Funding Amount
$1,735,574.00
Summary
Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces (BMIs) reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel within the brain. We propose to evaluate this device in animal studies, and continue on to a human clinical trial pilot study. The aim is to restore mechanical control over the physical env ....Persons affected by quadriplegia and hemiplegia from stroke and spinal cord injury have few treatment options. Brain Machine Interfaces (BMIs) reconnect brain to a prosthetic limb, bypassing damaged nervous system. Our group has developed a BMI that can be implanted minimally-invasively, inside a blood vessel within the brain. We propose to evaluate this device in animal studies, and continue on to a human clinical trial pilot study. The aim is to restore mechanical control over the physical environment for a paralysed patient.Read moreRead less
Preventing Early Internalising Problems In The Preschool Setting: Randomised Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$893,870.00
Summary
Internalising mental health problems reflect inner emotional distress and encompass all symptoms of anxiety and depression. Affecting 1 in 7 Australian school-age children, many internalising problems persist into adulthood, impacting on personal wellbeing, family relations and workforce capabilities. This randomised prevention trial in the preschool-setting, screens for children at-risk and tests if a parenting program can reduce internalising problems across the population by school-entry.
The Efficacy Of N-acetyl Cysteine As An Adjunctive Treatment For First Episode Psychosis
Funder
National Health and Medical Research Council
Funding Amount
$2,143,069.00
Summary
First episode psychosis may foreshadow devastating, chronic illness. Psychosis follows a staged, progressive pathway. There is evidence to suggest illness progression can be diminished and perhaps even averted if appropriate treatments are given at the early stages of illness. This project will test if N-acetycysteine (NAC) administered to young people who have experienced a first episode of psychosis can help prevent this early psychotic experience from developing into a chronic disorder.